Monoclonal Antibodies Targeting Surface-Exposed and Secreted Proteins from Staphylococci
Staphylococci (specifically <i>Staphylococcus aureus</i> and <i>Staphylococcus epidermidis</i>) are the causative agents of diseases ranging from superficial skin and soft tissue infections to severe conditions such as fatal pneumonia, bacteremia, sepsis and endocarditis. The...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/9/5/459 |
| _version_ | 1827693384542715904 |
|---|---|
| author | Pietro Speziale Giampiero Pietrocola |
| author_facet | Pietro Speziale Giampiero Pietrocola |
| author_sort | Pietro Speziale |
| collection | DOAJ |
| description | Staphylococci (specifically <i>Staphylococcus aureus</i> and <i>Staphylococcus epidermidis</i>) are the causative agents of diseases ranging from superficial skin and soft tissue infections to severe conditions such as fatal pneumonia, bacteremia, sepsis and endocarditis. The widespread and indiscriminate use of antibiotics has led to serious problems of resistance to staphylococcal disease and has generated a renewed interest in alternative therapeutic agents such as vaccines and antibodies. Staphylococci express a large repertoire of surface and secreted virulence factors, which provide mechanisms (adhesion, invasion and biofilm development among others) for both bacterial survival in the host and evasion from innate and adaptive immunity. Consequently, the development of antibodies that target specific antigens would provide an effective protective strategy against staphylococcal infections. In this review, we report an update on efforts to develop anti-staphylococci monoclonal antibodies (and their derivatives: minibodies, antibody–antibiotic conjugates) and the mechanism by which such antibodies can help fight infections. We also provide an overview of mAbs used in clinical trials and highlight their therapeutic potential in various infectious contexts. |
| first_indexed | 2024-03-10T11:42:53Z |
| format | Article |
| id | doaj.art-f1abd3bb1f8e4f58a4036cccdb4cded2 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T11:42:53Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-f1abd3bb1f8e4f58a4036cccdb4cded22023-11-21T18:22:21ZengMDPI AGVaccines2076-393X2021-05-019545910.3390/vaccines9050459Monoclonal Antibodies Targeting Surface-Exposed and Secreted Proteins from StaphylococciPietro Speziale0Giampiero Pietrocola1Department of Molecular Medicine, Unit of Biochemistry, University of Pavia, 27100 Pavia, ItalyDepartment of Molecular Medicine, Unit of Biochemistry, University of Pavia, 27100 Pavia, ItalyStaphylococci (specifically <i>Staphylococcus aureus</i> and <i>Staphylococcus epidermidis</i>) are the causative agents of diseases ranging from superficial skin and soft tissue infections to severe conditions such as fatal pneumonia, bacteremia, sepsis and endocarditis. The widespread and indiscriminate use of antibiotics has led to serious problems of resistance to staphylococcal disease and has generated a renewed interest in alternative therapeutic agents such as vaccines and antibodies. Staphylococci express a large repertoire of surface and secreted virulence factors, which provide mechanisms (adhesion, invasion and biofilm development among others) for both bacterial survival in the host and evasion from innate and adaptive immunity. Consequently, the development of antibodies that target specific antigens would provide an effective protective strategy against staphylococcal infections. In this review, we report an update on efforts to develop anti-staphylococci monoclonal antibodies (and their derivatives: minibodies, antibody–antibiotic conjugates) and the mechanism by which such antibodies can help fight infections. We also provide an overview of mAbs used in clinical trials and highlight their therapeutic potential in various infectious contexts.https://www.mdpi.com/2076-393X/9/5/459<i>Staphylococcus aureus</i><i>Staphylococcus epidermidis</i>virulence factorinfectious diseasesmonoclonal antibodypassive immunization |
| spellingShingle | Pietro Speziale Giampiero Pietrocola Monoclonal Antibodies Targeting Surface-Exposed and Secreted Proteins from Staphylococci Vaccines <i>Staphylococcus aureus</i> <i>Staphylococcus epidermidis</i> virulence factor infectious diseases monoclonal antibody passive immunization |
| title | Monoclonal Antibodies Targeting Surface-Exposed and Secreted Proteins from Staphylococci |
| title_full | Monoclonal Antibodies Targeting Surface-Exposed and Secreted Proteins from Staphylococci |
| title_fullStr | Monoclonal Antibodies Targeting Surface-Exposed and Secreted Proteins from Staphylococci |
| title_full_unstemmed | Monoclonal Antibodies Targeting Surface-Exposed and Secreted Proteins from Staphylococci |
| title_short | Monoclonal Antibodies Targeting Surface-Exposed and Secreted Proteins from Staphylococci |
| title_sort | monoclonal antibodies targeting surface exposed and secreted proteins from staphylococci |
| topic | <i>Staphylococcus aureus</i> <i>Staphylococcus epidermidis</i> virulence factor infectious diseases monoclonal antibody passive immunization |
| url | https://www.mdpi.com/2076-393X/9/5/459 |
| work_keys_str_mv | AT pietrospeziale monoclonalantibodiestargetingsurfaceexposedandsecretedproteinsfromstaphylococci AT giampieropietrocola monoclonalantibodiestargetingsurfaceexposedandsecretedproteinsfromstaphylococci |